Riddhi Siddhi Gluco Biols Ltd is Rated Strong Sell

27 minutes ago
share
Share Via
Riddhi Siddhi Gluco Biols Ltd is rated Strong Sell by MarketsMojo. This rating was last updated on 01 Feb 2025. However, the analysis and financial metrics discussed below reflect the company’s current position as of 27 September 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and overall outlook.
Riddhi Siddhi Gluco Biols Ltd is Rated Strong Sell

Understanding the Current Rating

The Strong Sell rating assigned to Riddhi Siddhi Gluco Biols Ltd indicates a cautious stance for investors, signalling significant concerns about the company’s financial health and future prospects. This rating is derived from a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall assessment and helps investors understand the risks involved in holding or acquiring this stock.

Quality Assessment

As of 27 September 2026, the company’s quality grade remains below average. This reflects persistent operational challenges and weak long-term fundamental strength. The company has been reporting operating losses, which undermines its ability to generate consistent profits. Its average Return on Equity (ROE) stands at a modest 2.87%, indicating limited profitability relative to shareholders’ funds. Furthermore, the company’s EBIT to interest coverage ratio is negative at -1.14, highlighting difficulties in servicing debt obligations. These factors collectively suggest that the company’s core business operations are under strain, which weighs heavily on its quality score.

Valuation Perspective

From a valuation standpoint, Riddhi Siddhi Gluco Biols Ltd is considered risky. The latest data shows a negative EBITDA of ₹-14.7 crores, signalling that the company is not generating sufficient earnings before interest, taxes, depreciation, and amortisation. Despite the stock delivering a 30.21% return over the past year, this performance is not supported by underlying profitability, which has declined sharply by 80.4%. The stock’s current valuation metrics suggest it is trading at levels that do not adequately reflect its deteriorating financial condition, increasing the risk for investors.

Financial Trend and Performance

The financial trend for Riddhi Siddhi Gluco Biols Ltd remains very negative. The company has declared losses for six consecutive quarters, with operating profit falling by 31.47% in the most recent period. Net sales for the latest six months have declined by 45.84% to ₹98.92 crores, while the net profit after tax (PAT) has also decreased by the same percentage, standing at a loss of ₹1.15 crores. Return on Capital Employed (ROCE) is low at 4.50%, reflecting inefficient use of capital. These figures indicate a sustained downturn in business performance, which is a critical factor in the current rating.

Technical Analysis

Technically, the stock shows a mildly bullish trend, which contrasts with the fundamental weaknesses. Over the past six months, the stock price has surged by 72.09%, and year-to-date gains stand at 76.82%. However, this price appreciation appears disconnected from the company’s financial realities, suggesting speculative interest or market momentum rather than fundamental strength. The one-day and one-week price changes are negative at -0.30% and -0.95% respectively, indicating some short-term volatility.

Promoter Confidence and Market Sentiment

Another important consideration is the reduction in promoter holdings. Promoters have decreased their stake by 11.55% over the previous quarter and currently hold 75% of the company. This decline in promoter confidence may signal concerns about the company’s future prospects and could influence investor sentiment negatively.

Summary for Investors

In summary, the Strong Sell rating for Riddhi Siddhi Gluco Biols Ltd reflects a combination of weak operational quality, risky valuation, deteriorating financial trends, and cautious technical signals. Investors should be aware that despite recent price gains, the company’s fundamentals remain under pressure, and the risks associated with holding this stock are considerable. This rating advises a conservative approach, favouring avoidance or exit until there is clear evidence of financial recovery and operational improvement.

Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.

  • - Investment Committee approved
  • - 50+ candidates screened
  • - Strong post-announcement performance

See Why It Was Chosen →

Contextualising the Stock’s Recent Returns

While the stock has delivered a 30.21% return over the past year and a remarkable 76.82% year-to-date gain, these returns are not supported by the company’s financial health. The disconnect between price performance and fundamentals suggests that the stock may be influenced by market speculation or sector rotation rather than intrinsic value improvements. Investors should exercise caution and prioritise fundamental analysis over short-term price movements when considering this stock.

Sector and Market Position

Riddhi Siddhi Gluco Biols Ltd operates within the Trading & Distributors sector and is classified as a microcap company. Microcap stocks often carry higher volatility and risk due to limited liquidity and smaller operational scale. The company’s current financial challenges and promoter stake reduction further compound these risks, making it a less favourable option for risk-averse investors.

Conclusion

Given the comprehensive evaluation of quality, valuation, financial trends, and technical factors, the Strong Sell rating for Riddhi Siddhi Gluco Biols Ltd is a clear signal for investors to approach this stock with caution. The company’s ongoing losses, negative cash flow indicators, and declining promoter confidence highlight significant challenges ahead. Until there is a demonstrable turnaround in fundamentals and financial health, the stock remains a high-risk proposition.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
Orient Technologies Ltd is Rated Strong Sell
27 minutes ago
share
Share Via
Vesuvius India Ltd is Rated Sell
27 minutes ago
share
Share Via
Precot Ltd is Rated Hold by MarketsMOJO
27 minutes ago
share
Share Via
Airo Lam Ltd is Rated Strong Sell
27 minutes ago
share
Share Via